- NCIt
- C203250
Loading cancer entity…
Loading cancer entity…
Clinical trials
65 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05773274 | Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial | recruiting | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 2 | Sep 24, 2026 | clinicaltrials |
| NCT03375320 | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | active not recruiting | Phase 3 | 298 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 |
| clinicaltrials |
| NCT04665739 | Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors | recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT00569127 | Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor | active not recruiting | Phase 3 | 427 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01841736 | Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors | active not recruiting | Phase 2 | 171 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT04993261 | An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors | active not recruiting | Early Phase 1 | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06016855 | Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors | recruiting | Phase 4 | 6 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07150546 | Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. | recruiting | Phase 1 | 15 | Emory UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04907643 | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | recruiting | N/A | 360 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06148636 | A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors | active not recruiting | Early Phase 1 | 24 | David BushnellOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT07188441 | Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin. | recruiting | Phase 2 | 40 | Chengcheng GuoOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06395402 | 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry(LUMOD-ID) | recruiting | Phase 2 | 120 | University of IowaOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05111509 | A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent | active not recruiting | Early Phase 1 | 20 | Yusuf MendaOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04520932 | Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors(RFANET) | recruiting | N/A | 82 | Institut Paoli-CalmettesOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT04735198 | Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.(TNE-IDC-COLE) | recruiting | N/A | 100 | Hospital Universitari de BellvitgeOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT04464122 | Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)(REBORN) | recruiting | — | 60 | University of Roma La SapienzaOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06855095 | Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial(ATSA) | recruiting | Phase 2 / Phase 3 | 39 | The Netherlands Cancer InstituteOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06472388 | Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors(EVENET) | recruiting | Phase 2 | 100 | AC Camargo Cancer CenterOTHER | 1 | Jun 25, 2024 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials